Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan
| العنوان: | Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan |
|---|---|
| المؤلفون: | Robert T. Jensen, Lingaku Lee, Toshihiko Masui, Izumi Komoto, Atsuko Kasajima, Noritoshi Kobayashi, Masayuki Hijioka, Masayuki Imamura, Susumu Hijioka, Yuji Nakamoto, Tetsuhide Ito, Hisato Igarashi |
| المصدر: | Journal of Gastroenterology. 52:9-18 |
| بيانات النشر: | Springer Science and Business Media LLC, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | medicine.medical_specialty, Pathology, Gene mutation, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Japan, Surgical oncology, Internal medicine, Humans, Medicine, Somatostatin receptor 2, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Grading (tumors), Neoplasm Staging, biology, business.industry, Gastroenterology, Chromogranin A, Hepatology, Prognosis, medicine.disease, Combined Modality Therapy, Pancreatic Neoplasms, Pancreatic Neuroendocrine Neoplasm, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, biology.protein, 030211 gastroenterology & hepatology, Neoplasm Grading, business |
| الوصف: | Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 % according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (111In-octreoscan) has also been approved in Japan. This advancement will undoubtedly contribute to the localization diagnosis, the identification of remote metastasis, and assessments of the treatment responses of PNEN. Finally, regarding the treatment strategy for PNEN, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced PNEN. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required. |
| تدمد: | 1435-5922 0944-1174 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d06712905b2a27668d25bfcfe97704 https://doi.org/10.1007/s00535-016-1250-9 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a7d06712905b2a27668d25bfcfe97704 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14355922 09441174 |
|---|